35Pharma
35Pharma is a clinical-stage biopharmaceutical company focused on designing and developing TGF-beta superfamily therapeutics.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Acquired by GGlaxoSmithKline on · The Globe and Mail.
Signals
Website registeredJan 26, 2022 (4 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | undisclosed | fundraisingfox.com |
Timeline
- Acquired by
GGlaxoSmithKline
Source: The Globe and Mail - Website created
Team
IA
Ilia A. Tikhomirov Chief Executive OfficerMO
Maureen O’Connor-McCourt Chief Scientific OfficerWB
Walter Blättler Chairman
Investors
CColumbia Threadneedle Investments
DDeep Track Capital
FFrazier Life Scienceslead investor
JJanus Henderson Investors
LLogos Capital
MMarshall Wace
PParadigm BioCapital Advisors
SSurveyor Capital
VvenBio Partners
VVivo Capital
Companies like 35Pharma
BBionyra$165M Series A · Jun 2026
RR1 Therapeutics$80.5M Series A · Sep 2026
AAdjuvia Therapeutics$8M Seed · Jul 2026
AApollo Therapeutics$226.5M Series B+ · Sep 2023NNoema PharmaSeries B+ · Nov 2025
KKALA BIO$10M · Dec 2025
Other companies backed by Frazier Life Sciences
RRQ Bio$115M Series A · Jun 2026
IImmutrin$86.45M Series A · Mar 2026
AAngitia Bio$130M Series B+ · Feb 2026
AAirNexis Therapeutics$200M Series A · Jan 2026
AAspen Neuroscience$115M Series B+ · Nov 2025
TTubulis$360M Series B+ · Oct 2025
Frazier Life Sciences portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/35pharma (get a free API key).